In a potential advance for melanoma patients, researchers at ChristianaCare’s Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms of this dangerous skin cancer that renders promising treatments ineffective.
Health Professionals
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy.
Melanoma Risk Doubled for Monoclonal B-Cell Lymphocytosis
Patients who have the low-count chronic lymphocytic leukemia (CLL) phenotype monoclonal B-cell lymphocytosis (LC-MBL) have a nearly doubled risk for melanoma, according to a study in Journal of Clinical Oncology.
Study Highlights Racial Differences in Second Primary Melanoma
White patients have the highest absolute risk for a second primary melanoma, while Black and Asian or Pacific Islander patients have the highest relative risk compared with the general population, a study analyzing Surveillance, Epidemiology, and End Results (SEER) data report.